Compare SSYS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSYS | DRUG |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.8M | 856.4M |
| IPO Year | 2012 | 2020 |
| Metric | SSYS | DRUG |
|---|---|---|
| Price | $8.56 | $80.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $12.33 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 865.9K | 73.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.69 | N/A |
| Revenue Next Year | $6.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $23.18 |
| 52 Week High | $12.78 | $123.75 |
| Indicator | SSYS | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 48.24 |
| Support Level | $8.34 | $77.80 |
| Resistance Level | $11.43 | $91.00 |
| Average True Range (ATR) | 0.47 | 4.77 |
| MACD | -0.20 | -0.62 |
| Stochastic Oscillator | 11.74 | 40.88 |
Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.